, Volume 66, Issue 6, pp 731–741 | Cite as

Shift in the Epidemiology of Pertussis Infection

An Indication for Pertussis Vaccine Boosters for Adults?
Current Opinion


Pertussis vaccination of young children has been effective in reducing the overall disease burden due to Bordetella pertussis in many countries. However, the disease has not been eliminated, although humans are the only known host of this pathogen. In fact, in some countries, the number of reported cases has increased dramatically from their nadir and epidemics routinely occur. In areas where >80% of children <2 years of age have been vaccinated, the burden of disease has shifted from elementary school-aged children (who are presumably protected by vaccination) to young infants (<6 months of age) and individuals >11 years of age. With the recent availability of acellular pertussis vaccines for older children to adults, consideration of a change in current vaccination policy is necessary in order to provide better disease control.



Dr Sylvia Yeh is funded by National Institutes of Health/National Institute of Allergy and Infectious Diseases K23 grant AI49959. The authors have no conflicts of interest directly relevant to the contents of this article.


  1. 1.
    Cherry JD, Heininger U. Pertussis and other Bordetella infections. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. 4th ed. Philadelphia (PA): WB Saunders Company, 1998: 1423–40Google Scholar
  2. 2.
    Laring JS, Hay M. Whooping-cough: its prevalence and mortality in Aberdeen. Public Health 1902; 14: 584–98CrossRefGoogle Scholar
  3. 3.
    Mannerstedt G. Pertussis in adults. J Pediatr 1934; 5: 596–600CrossRefGoogle Scholar
  4. 4.
    Brennan M, Strebel P, George H, et al. Evidence for transmission of pertussis in schools, Massachusetts, 1996: epidemiologic data supported by pulsed-field gel electrophoresis. J Infect Dis 2000; 181: 210–5PubMedCrossRefGoogle Scholar
  5. 5.
    Gehanno JF, Pestel-Caron M, Nouvellon M, et al. Nosocomial pertussis in healthcare workers from a pediatric emergency unit in France. Infect Control Hosp Epidemiol 1999; 20: 549–52PubMedCrossRefGoogle Scholar
  6. 6.
    Centers for Disease Control and Prevention. Pertussis outbreak — Vermont 1996. MMWR 1997; 46: 8226Google Scholar
  7. 7.
    de Melker HE, Conyn-van Spaendonck MAE, Rumke HC, et al. Pertussis in the Netherlands: an outbreak despite high levels of immunization with whole cell vaccine. Emerg Infect Dis 1997; 3: 175–8PubMedCrossRefGoogle Scholar
  8. 8.
    Klement E, Uliel L, Engel I, et al. An outbreak of pertussis among young Israeli soldiers. Epidemiol Infect 2003; 131: 1049–54PubMedCrossRefGoogle Scholar
  9. 9.
    van der Zee A, Mooi F, van Enbden J, et al. Molecular evolution and host adaptation of Bordetella spp: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences. J Bacteriol 1997; 179: 6609–17PubMedGoogle Scholar
  10. 10.
    Heininger U, Stehr K, Schmitt-Grohe S, et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 1994; 13: 306–9PubMedCrossRefGoogle Scholar
  11. 11.
    Hewlett EL. A commentary on the pathogenesis of pertussis. Clin Infect Dis 1999; 28 Suppl. 2: S94–8PubMedCrossRefGoogle Scholar
  12. 12.
    Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005; 5: S10–18Google Scholar
  13. 13.
    Edwards KM, Decker MD, Mortimer EA. Pertussis vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia (PA): WB Saunders Company, 1999: 293–344Google Scholar
  14. 14.
    Bass JW, Stephenson SR. The return of pertussis. Pediatr Infect Dis 1978; 6: 141–4Google Scholar
  15. 15.
    Mertsola J, Ruuskanen O, Eerola E, et al. Intrafamilial spread of pertussis. J Pediatr 1983; 103: 359–63PubMedCrossRefGoogle Scholar
  16. 16.
    Cherry JD. The epidemiology of pertussis and pertussis immunization on in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr 1984; 14: 1–78PubMedGoogle Scholar
  17. 17.
    Centers for Disease Control and Prevention. Pertussis: United States, January 1992–June 1995. MMWR 1995; 44: 525–9Google Scholar
  18. 18.
    Centers for Diseases Control and Prevention. Pertussis-United States, 1997–2002. MMWR 2002; 51(04): 73–6Google Scholar
  19. 19.
    Health Canada, Population and Public Health Branco. Notifiable disease on-line, 1986–1998 [online]. Available from URL: http://cutjera/oc/gc/ca/dsol/ndis/c-age_e.html [Accessed 2005 Jan 24]
  20. 20.
    Andrews R, Herceg A, Toberts C. Pertussis notifications in Australia 1991 to 1997. Commun Dis Intell 1997; 21: 145–8PubMedGoogle Scholar
  21. 21.
    World Health Organization. WHO vaccine-preventable diseases: monitoring system 2004 global summary [online]. Available from URL: http://www.who.int/vaccines-documents/GlobalSummary/GlobalSummary.pdf [Accessed 2005 Jan 24]
  22. 22.
    Murphy T, Bisgard K, Sanden G. Diagnosis and laboratory methods. In: Guidelines for the control of pertussis outbreaks. Atlanta (GA): Centers for Disease Control and Prevention, 2000Google Scholar
  23. 23.
    Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353: 1555–63PubMedCrossRefGoogle Scholar
  24. 24.
    Kosters K, Riffelmann M, Wirsing von Konig CH. Evaluation of a real-time PCR assay for detection of Bordetella pertussis and B. parapertussis in clinical samples. J Med Microbiol 2001; 50: 436–40Google Scholar
  25. 25.
    Riffelmann M, Wirsing von Konig CH, Caro V, et al. Nucleic acid amplification tests for diagnosis of Bordetella infections. J Clin Microbiol 2005; 43: 4925–9PubMedCrossRefGoogle Scholar
  26. 26.
    Marchant CD, Loughlin AM, Lett SM, et al. Pertussis in Massachusetts, 1981–1991: incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis 1994; 169: 1297–305PubMedCrossRefGoogle Scholar
  27. 27.
    Baughman AL, Bisgard KM, Edwards KM, et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 2004; 11: 1045–53PubMedGoogle Scholar
  28. 28.
    Cattaneo LA, Reed GW, Haase DH, et al. The seroepidemiology of Bordetella pertussis infection: a study of persons ages 1–65. J Infect Dis 1996; 173: 1256–9PubMedCrossRefGoogle Scholar
  29. 29.
    Cromer BA, Goydos J, Hackell J, et al. Unrecognized pertussis infections in adolescents. Am J Dis Child 1993; 147: 575–7PubMedGoogle Scholar
  30. 30.
    Wright SW, Edwards KM, Decker MD, et al. Pertussis seroprevalence in Emergency Department staff. Ann Emerg Med 1994; 21: 413–7CrossRefGoogle Scholar
  31. 31.
    Nennig ME, Shinefield HR, Edwards KM, et al. Prevalence and incidence of adult pertussis in an urban population. JAMA 1996; 275: 1672–4PubMedCrossRefGoogle Scholar
  32. 32.
    Yih WK, Lett SM, de Vignes FN, et al. The increasing incidence of pertussis in Massachusetts adolescents and adults 1989–1998. J Infect Dis 2000; 182: 1409–16PubMedCrossRefGoogle Scholar
  33. 33.
    Wright SW, Decker MD, Edwards KM. Incidence of pertussis infection in healthcare workers. Infect Control Hosp Epidemiol 1999; 20: 120–3PubMedCrossRefGoogle Scholar
  34. 34.
    Mink CM, Cherry JD, Christ PD, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992; 14: 464–71PubMedCrossRefGoogle Scholar
  35. 35.
    Wright SW, Edwards KK, Decker MD, et al. Pertussis infection in adults with persistent cough. JAMA 1995; 273: 1044–6PubMedCrossRefGoogle Scholar
  36. 36.
    Rosenthal S, Stebel P, Cassiday P, et al. Pertussis infection among adults during the 1993 outbreak in Chicago. J Infect Dis 1995; 171: 1650–2PubMedCrossRefGoogle Scholar
  37. 37.
    Jansen DL, Gray GC, Putman SD, et al. Evaluation of pertussis in US Marine corp trainees. Clin Infect Dis 1997; 25: 1099–107PubMedCrossRefGoogle Scholar
  38. 38.
    Senzilet LD, Halperin SA, Spika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001; 32: 1691–87PubMedCrossRefGoogle Scholar
  39. 39.
    Roberson PW, Goldberg H, Jarvie BH, et al. Bordetella pertussis infection: a cause of persistent cough in adults. Med J Aust 1987; 146: 522–5Google Scholar
  40. 40.
    Gilberg S, Njamkepo E, Parent du Ch↦elet I, et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis 2002; 186: 415–8PubMedCrossRefGoogle Scholar
  41. 41.
    Davis J. Clinical and economic effects of pertussis outbreaks. Pediatr Infect Dis J 2005 Jun; 24 (6 Suppl.): S109–16PubMedGoogle Scholar
  42. 42.
    Centers for Disease Control and Prevention National Immunization Program. Record of the meeting of the Advisory Committee on Immunization Practices, 2005 Feb 10–11 [online]. Available from URL: http://www.cdc.gov/nip/ACIP/minutes/acip-min-febO5.pdf [Accessed 2006 Mar 23]
  43. 43.
    Mortimer EA. Pertussis and its prevention: a family affair. J Infect Dis 1990; 161: 473–9PubMedCrossRefGoogle Scholar
  44. 44.
    Valenti WM, Pincus PH, Messner MK. Nosocomial pertussis: possible spread by a hospital visitor. Am J Dis Child 1980; 134: 520–7PubMedGoogle Scholar
  45. 45.
    Beiter A, Lewis K, Pineda EF, et al. Unrecognized maternal peripartum pertussis with subsequent fatal neonatal pertussis. Obstet Gynecol 1993; 82: 691–3PubMedGoogle Scholar
  46. 46.
    Deen JL, Mink CM, Cherry JD, et al. A household contact study of Bordetella pertussis infections. Clin Infect Dis 1995; 21: 1211–9PubMedCrossRefGoogle Scholar
  47. 47.
    Bisgard KM, Pascaul FB, Ehresmann KR, et al. Infant pertussis, who was the source? Pediatr Infect Dis J 2004; 23: 985–9PubMedCrossRefGoogle Scholar
  48. 48.
    Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognized pertussis in UK infants. Arch Dis Child 2003; 88: 202–6CrossRefGoogle Scholar
  49. 49.
    Grimpel E, Baron S, Levy-Bruhl D, et al. Influence of vaccination coverage on pertussis transmission in France. Lancet 1999; 345: 1699–700CrossRefGoogle Scholar
  50. 50.
    Schmitt-Grohe S, Cherry JD, Heininger U, et al. Pertussis in German adults. Clin Infect Dis 1995; 21: 860–6PubMedCrossRefGoogle Scholar
  51. 51.
    Maclean DW. Adults with pertussis. J R Coll Gen Pract 1982; 32: 298–300PubMedGoogle Scholar
  52. 52.
    Aoyama T, Takeuchi Y, Goto A, et al. Pertussis in adults. Am J Dis Child 1992; 146: 163–6PubMedGoogle Scholar
  53. 53.
    Edward R, Edwards K. Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J 2005; 5: s44–7Google Scholar
  54. 54.
    Long SS, Welkon CI, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 1990; 161: 480–6PubMedCrossRefGoogle Scholar
  55. 55.
    Halperin SA, Wang EEL, Law B, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991–1997: report of the Immunization Monitoring Program-Active (IMPACT). Clin Infect Dis 1999; 28(6): 1238–43PubMedCrossRefGoogle Scholar
  56. 56.
    De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182: 174–9PubMedCrossRefGoogle Scholar
  57. 57.
    Lee LH, Pichichero ME. Costs of illness due to Bordetella pertussis in families. Arch Fam Med 2000; 9: 989–96PubMedCrossRefGoogle Scholar
  58. 58.
    Purdy KW, Hay JW, Botteman MF, et al. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 2004; 39: 20–8PubMedCrossRefGoogle Scholar
  59. 59.
    Calugar A, Ortega-Sanchez I, Tiwari T, et al. Nosocomial pertussis: cost of an outbreak and benefits of vaccinating health care workers. Clin Infect Dis 2006; 42: 981–8PubMedCrossRefGoogle Scholar
  60. 60.
    FDA. Product approval information: BOOSTRIX™ licensing action [online]. Available from URL: http://www.fda.gov/cber/products/tdapgla050305.htm [Accessed 2006 Mar 23]
  61. 61.
    FDA. Product approval information: ADACEL™ licensing action.… [online]. Available from URL: http://www.fda.gov/cber/products/tdapave061005.htm [Accessed 2006 Mar 23]
  62. 62.
    Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulation of five new strategies. Vaccine 2004; 22: 3154–65PubMedCrossRefGoogle Scholar
  63. 63.
    Lee GM, LeBaron C, Murphy TV, et al. Pertussis in adolescents and adults: should we vaccinate? Pediatrics 2005; 115: 1675–84PubMedCrossRefGoogle Scholar
  64. 64.
    Iskedjian M, Walker JH, Hemels ME. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 2004; 22: 4215–27PubMedCrossRefGoogle Scholar
  65. 65.
    Scuffham PA, McIntyre PB. Pertussis vaccination strategies for neonates: an exploratory cost-effectiveness analysis. Vaccine 2004; 22: 2953–64PubMedCrossRefGoogle Scholar
  66. 66.
    Hethcote HW, Horby P, Mclntyre P. Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 2004; 22: 2181–91PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.UCLA Center for Vaccine Research at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterTorranceUSA
  2. 2.Miller Children’s HospitalLong BeachUSA
  3. 3.Harbor-UCLA Medical Center/David Geffen School of Medicine at UCLATorranceUSA

Personalised recommendations